Clearside Biomedical's axitinib injectable suspension phase 1/2a trial enrolls first patients

January 12, 2021
OT Staff Reports

Delivery into the suprachoroidal space may potentially extend the duration of therapeutic action and reduce or relieve the treatment burden for wet AMD.

Related Content:

Retina | News | Clinical